|
1
|
Alter MJ, Mast EE, Moyer LA and Margolis
HS: Hepatitis C. Infect Dis Clin North Am. 12:13–26. 1998.
View Article : Google Scholar
|
|
2
|
Chen SL and Morgan TR: The natural history
of hepatitis C virus (HCV) infection. Int J Med Sci. 3:47–52.
1997.
|
|
3
|
Lin W, Kim SS, Yeung E, Kamegaya Y,
Blackard JT, Kim KA, Holtzman MJ and Chung RT: Hepatitis C virus
core protein blocks interferon signaling by interaction with the
STAT1 SH2 domain. J Virol. 80:9226–9235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melén K, Fagerlund R, Nyqvist M, Keskinen
P and Julkunen I: Expression of hepatitis C virus core protein
inhibits interferon-induced nuclear import of STATs. J Med Virol.
73:536–547. 2004.PubMed/NCBI
|
|
5
|
de Lucas S, Bartolome J and Carreno V:
Hepatitis C virus core protein down-regulates transcription of
interferon-induced antiviral genes. J Infect Dis. 191:93–99.
2005.PubMed/NCBI
|
|
6
|
Hadziyannis S, Sette H Jr, Morgan TR,
Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr,
Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A and Ackrill
AM; PEGASYS International Study Group. Peginterferon-α2a and
ribavirin therapy in chronic hepatitis C: A randomized study of
treatment duration and ribavirin dose. Annal Intern Med.
140:346–355. 2004.
|
|
7
|
Dore GJ, Matthews GV and Rockstroh J:
Future of hepatitis C therapy: development of direct-acting
antivirals. Curr Opin HIV AIDS. 6:508–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Asahina Y, Izumi N, Enomoto N, Uchihara M,
Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H,
Kitamura T and Miyake S: Mutagenic effects of ribavirin and
response to interferon/ribavirin combination therapy in chronic
hepatitis C. J Hepatol. 43:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chung RT, Gale M Jr, Polyak SJ, Lemon SM,
Liang TJ and Hoofnagle JH: Mechanisms of action of interferon and
ribavirin in chronic hepatitis C: Summary of a workshop.
Hepatology. 47:306–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Herrmann E, Lee JH, Marinos G, Modi M and
Zeuzem S: Effect of ribavirin on hepatitis C viral kinetics in
patients treated with pegylated interferon. Hepatology.
37:1351–1358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba
KI, Orito E, Mukaide M, Williams R and Lau JY: New hepatitis C
virus (HCV) genotyping system that allows for identification of HCV
genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol.
35:201–207. 1997.PubMed/NCBI
|
|
12
|
Waheed Y, Tahir S, Ahmad T and Qadri I:
Sequence comparison and phylogenetic analysis of core gene of
hepatitis C virus from Pakistani population. Afr J Biotechnol.
9:4561–4567. 2010.
|
|
13
|
Wu S, Skolnick J and Zhang Y: Ab initio
modeling of small proteins by iterative TASSER simulations. BMC
Biol. 5:172007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Vries SJ, van Dijk M and Bonvin AM: The
HADDOCK web server for data-driven biomolecular docking. Nat
Protoc. 5:883–897. 2010.PubMed/NCBI
|
|
15
|
Prevelige PE Jr: Inhibiting virus-capsid
assembly by altering the polymerisation pathway. Trends Biotechnol.
16:61–65. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Klein KC, Dellos SR and Lingappa JR:
Identification of residues in the hepatitis C virus core protein
that are critical for capsid assembly in a cell-free system. J
Virol. 79:6814–6826. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang X, Wagoner J, Negash A, Austin M,
McLauchlan J, Hahn YS, Rosen HR and Polyak SJ: Functional
characterization of core genes from patients with acute hepatitis
C. J Infect Dis. 201:912–922. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hourioux C, Ait-Goughoulte M, Patient R,
Fouquenet D, Arcanger-Doudet F, Brand D, Martin A and Roingeard P:
Core protein domains involved in hepatitis C virus-like particle
assembly and budding at the endoplasmic reticulum membrane. Cell
Microbiol. 9:1014–1027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin W, Choe WH, Hiasa Y, Kamegaya Y,
Blackard JT, Schmidt EV and Chung RT: Hepatitis C virus expression
suppresses interferon signaling by degrading STAT1.
Gastroenterology. 128:1034–1041. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akuta N, Suzuki F, Sezaki H, Suzuki Y,
Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J,
Matsuda M, Kobayashi M, Arase Y, Ikeda K and Kumada H: Association
of amino acid substitution pattern in core protein of hepatitis C
virus genotype 1b high viral load and non-virological response to
interferon-ribavirin combination therapy. Intervirology.
48:372–380. 2005. View Article : Google Scholar
|
|
21
|
Akuta N, Suzuki F, Hirakawa M, Kawamura Y,
Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M,
Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y and Kumada H:
Amino acid substitution in hepatitis C virus core region and
genetic variation near the interleukin 28B gene predict viral
response to telaprevir with peginterferon and ribavirin.
Hepatology. 52:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hofmann WP, Polta A, Herrmann E, Mihm U,
Kronenberger B, Sonntag T, Lohmann V, Schönberger B, Zeuzem S and
Sarrazin C: Mutagenic effect of ribavirin on hepatitis C
nonstructural 5B quasispecies in vitro and during antiviral
therapy. Gastroenterology. 132:921–930. 2007. View Article : Google Scholar : PubMed/NCBI
|
